603077 和邦生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.9976.63322.82023.7790.370
总资产报酬率 ROA (%)0.7575.27618.11718.4830.280
投入资产回报率 ROIC (%)0.8385.90220.34920.4860.309

边际利润分析
销售毛利率 (%)11.16923.26142.85341.37918.796
营业利润率 (%)5.06917.47234.36735.9568.373
息税前利润/营业总收入 (%)5.37017.03834.53336.6742.595
净利润/营业总收入 (%)3.87914.49129.22230.3030.055

收益指标分析
经营活动净收益/利润总额(%)99.55697.559100.12499.2542,524.293
价值变动净收益/利润总额(%)-0.1224.8970.4870.753154.187
营业外收支净额/利润总额(%)-0.182-0.379-0.058-0.355-2,686.305

偿债能力分析
流动比率 (X)1.9562.6852.6031.4871.053
速动比率 (X)1.1361.4852.0471.1950.852
资产负债率 (%)25.18917.61918.00418.32923.287
带息债务/全部投入资本 (%)19.36210.4039.68610.54016.961
股东权益/带息债务 (%)411.568851.542922.881843.249488.789
股东权益/负债合计 (%)287.320452.708440.575433.641324.591
利息保障倍数 (X)17.325-46.256186.63543.3981.131

营运能力分析
应收账款周转天数 (天)37.99135.81117.61018.32136.070
存货周转天数 (天)189.575172.22872.18747.51582.198